indazoles has been researched along with Biliary Tract Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furuse, J; Kasuga, A; Kawai, K; Kobayashi, T; Nagashima, F; Naruge, D; Okano, N | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
2 trial(s) available for indazoles and Biliary Tract Cancer
| Article | Year |
|---|---|
Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Biliary Tract Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2017 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |